Publicaciones en colaboración con investigadores/as de Universidade de São Paulo (12)

2023

  1. Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 4, pp. 680-688

2022

  1. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

    Blood, Vol. 140, Núm. 5, pp. 419-437

2021

  1. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: Final data

    Blood Advances, Vol. 5, pp. 5098-5106

  2. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

    European Journal of Cancer, Vol. 148, pp. 411-421

  3. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*

    British Journal of Dermatology, Vol. 184, Núm. 3, pp. 524-531

  4. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*

    British Journal of Dermatology, Vol. 184, Núm. 4, pp. 722-730

2020

  1. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study

    European Journal of Cancer, Vol. 133, pp. 120-130

2017

  1. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    The Lancet, Vol. 390, Núm. 10094, pp. 555-566

  2. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: A multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

    Annals of Oncology, Vol. 28, Núm. 10, pp. 2517-2525

2015

  1. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model

    Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3766-3773

2011

  1. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

    Journal of Clinical Oncology, Vol. 29, Núm. 18, pp. 2598-2607

  2. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

    Blood